Innovation Pharmaceuticals (IPIX) stock price, revenue, and financials

Innovation Pharmaceuticals market cap is $143.1 m, and annual revenue was $423 k in FY 2020

$143.1 M

IPIX Mkt cap, 26-Feb-2021
Innovation Pharmaceuticals Net income (Q2, 2021)-6.2 M
Innovation Pharmaceuticals EBIT (Q2, 2021)-3.4 M
Innovation Pharmaceuticals Cash, 31-Dec-20208.2 M
Innovation Pharmaceuticals EV137 M

Innovation Pharmaceuticals Income Statement

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

423.0k

R&D expense

632.8k1.5m6.3m10.5m9.0m12.8m11.4m4.3m2.8m

General and administrative expense

205.8k369.9k872.0k1.2m1.9m1.3m1.4m1.2m1.4m

Operating expense total

838.6k1.9m7.2m11.7m10.9m14.1m12.8m5.5m4.2m

Depreciation and amortization

1.0k

EBIT

(4.2m)(3.0m)(8.0m)(13.0m)(12.7m)(15.3m)(13.9m)(6.5m)(4.6m)

EBIT margin, %

(1096%)

Interest expense

257.4k241.5k209.0k189.0k198.0k200.0k2.4m197.0k208.0k

Interest income

1.0k4.0k4.0k2.0k1.0k

Pre tax profit

(4.9m)(3.2m)(8.2m)(13.1m)(12.9m)(15.5m)(16.4m)(8.7m)(6.6m)

Income tax expense

Net Income

(4.9m)(3.2m)(8.2m)(13.1m)(12.9m)(15.5m)(16.4m)(8.7m)(6.6m)

Innovation Pharmaceuticals Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

27.7k3.0m6.3m4.1m2.4m579.0k6.0m

Prepaid Expenses

325.04.8k568.0k347.0k308.0k29.0k46.0k92.0k

Current Assets

28.0k3.0m5.6m8.8m6.7m4.5m2.6m625.0k6.1m

PP&E

39.0k38.0k120.0k2.0k1.0k

Total Assets

28.0k3.0m10.9m14.3m11.4m9.1m6.5m4.0m9.2m

Accounts Payable

2.0m1.8m2.7m1.8m42.2m4.7m3.2m2.0m

Dividends Payable

13.0k

Short-term debt

2.0m

Current Liabilities

7.4m8.1m9.6m7.3m8.5m10.6m8.7m7.3m7.4m

Long-term debt

417.0k

Total Debt

2.5m

Total Liabilities

7.7m8.1m9.6m7.3m8.5m10.6m8.7m8.2m7.8m

Preferred Stock

Additional Paid-in Capital

9.2m14.9m29.2m48.2m57.0m68.3m83.7m90.5m102.8m

Retained Earnings

(28.0m)(41.2m)(54.0m)(69.6m)(85.9m)(94.6m)(101.2m)

Total Equity

(7.6m)(5.2m)1.2m7.0m3.0m(1.5m)(2.2m)(4.1m)1.5m

Financial Leverage

0 x-0.6 x9 x2 x3.9 x-6.2 x-3 x-1 x6.3 x

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021

Cash

9.0k864.6k93.7k124.9k222.9k1.1m5.0m5.1m7.1m9.5m10.8m7.8m6.2m5.3m5.6m3.9m5.6m2.9m3.2m1.3m306.0k748.0k468.0k910.0k187.0k775.0k8.2m

Accounts Receivable

403.0k

Prepaid Expenses

28.8k18.1k6.6k16.0k12.2k7.5k165.2k213.0k133.0k98.0k623.0k257.0k174.0k440.0k181.0k199.0k107.0k187.0k94.0k40.0k55.0k104.0k55.0k57.0k29.0k36.0k84.0k

Current Assets

37.8k882.7k100.3k140.8k235.1k1.1m5.5m5.4m7.2m9.6m11.4m8.0m6.4m5.8m6.2m4.1m5.7m3.2m3.4m1.5m361.0k852.0k523.0k967.0k216.0k811.0k8.3m

PP&E

41.0k45.0k43.0k40.0k35.0k32.0k93.0k88.0k139.0k129.0k111.0k102.0k93.0k2.0k1.0k1.0k

Total Assets

37.8k882.7k100.3k140.8k534.9k1.3m10.6m10.3m12.5m14.9m17.1m13.5m11.9m11.3m10.9m8.8m10.5m7.7m7.7m5.8m4.3m4.4m4.0m4.3m3.5m4.0m12.4m

Accounts Payable

1.9m2.0m2.0m1.9m2.0m2.0m1.8m1.8m2.3m2.1m2.0m2.1m2.1m3.1m3.7m3.2m4.2m5.4m4.9m4.1m2.8m2.4m2.3m2.0m

Short-term debt

167.1k167.1k2.0m1.7m

Current Liabilities

6.8m8.5m7.2m7.5m7.9m8.2m9.3m9.4m8.0m7.7m7.3m7.5m7.6m8.4m8.8m8.7m9.3m10.8m10.6m9.5m8.3m8.0m7.6m7.5m7.8m7.8m6.8m

Long-term debt

523.0k489.0k454.0k338.0k

Total Debt

167.1k167.1k523.0k489.0k2.4m2.0m

Total Liabilities

7.3m9.0m7.4m7.8m8.2m8.2m8.0m7.7m7.3m7.5m7.6m8.4m8.8m8.7m9.3m10.8m10.6m9.5m8.3m8.6m8.3m8.9m9.1m8.5m9.0m

Common Stock

10.7k12.0k12.0k12.0k12.0k27.0k

Preferred Stock

Additional Paid-in Capital

5.8m7.0m7.9m9.9m10.6m12.1m23.6m25.6m36.9m42.3m47.8m60.0k51.3m53.6m59.2m60.5m65.5m71.2m76.1m77.3m84.0m87.8m88.9m91.7m93.3m95.4m114.2m

Retained Earnings

(32.4m)(35.2m)(38.1m)(43.7m)(47.1m)(50.8m)(57.0m)(60.4m)(64.3m)(74.1m)(78.6m)(81.1m)(88.0m)(91.9m)(93.1m)(96.1m)(98.8m)(99.8m)(108.6m)

Total Equity

(7.3m)(8.1m)(7.3m)(7.7m)(7.7m)(6.8m)1.2m910.9k4.5m7.1m9.8m6.0m4.3m2.9m2.1m136.0k1.2m(3.2m)(2.9m)(3.7m)(4.0m)(4.2m)(4.3m)(4.5m)(5.6m)(4.5m)3.4m

Financial Leverage

0 x-0.1 x0 x0 x-0.1 x-0.2 x8.6 x11.3 x2.8 x2.1 x1.7 x2.2 x2.8 x3.9 x5.1 x64.6 x8.9 x-2.4 x-2.7 x-1.5 x-1.1 x-1 x-0.9 x-0.9 x-0.6 x-0.9 x3.6 x

Innovation Pharmaceuticals Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(4.9m)(3.2m)(8.2m)(13.1m)(12.9m)(15.5m)(16.4m)(8.7m)(6.6m)

Depreciation and Amortization

(616.0)289.0k404.0k420.0k405.0k413.0k371.0k373.0k

Accounts Receivable

204.1k

Accounts Payable

(173.5k)(116.9k)815.0k(826.0k)1.7m1.2m(1.5m)(1.1m)(84.0k)

Cash From Operating Activities

(693.9k)(1.9m)(7.5m)(13.1m)(9.9m)(11.7m)(13.3m)(6.3m)(4.2m)

Cash From Investing Activities

(11.0k)(2.6m)(459.0k)(414.0k)(336.0k)(104.0k)(46.0k)(91.0k)

Cash From Financing Activities

652.9k4.8m12.2m17.0m8.2m9.9m11.7m4.5m9.7m

Net Change in Cash

(41.0k)2.9m2.0m3.4m(2.1m)(2.2m)(1.7m)(1.8m)5.4m

Interest Paid

14.8k222.9k259.0k366.0k235.0k44.0k171.0k143.0k216.0k

Income Taxes Paid

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021

Net Income

(961.5k)(3.0m)(3.3m)(469.0k)(1.2m)(2.1m)(2.6m)(4.9m)(4.4m)(7.1m)(10.0m)(2.6m)(5.9m)(9.6m)(3.0m)(6.4m)(10.3m)(4.5m)(9.1m)(11.5m)(2.0m)(6.0m)(7.2m)(1.5m)(4.2m)(5.2m)(7.3m)

Depreciation and Amortization

(554.0)101.8k197.9k99.0k202.0k304.0k100.0k209.0k321.0k96.0k198.0k301.0k105.0k210.0k317.0k94.0k186.0k278.0k93.0k187.0k280.0k188.0k

Accounts Receivable

204.1k204.1k204.1k403.0k

Accounts Payable

(222.0k)(101.7k)(142.2k)(99.8k)22.0k16.2k(72.2k)(30.8k)(407.0k)(580.0k)(619.0k)219.0k259.0k1.3m190.0k(305.0k)664.0k711.0k151.0k(578.0k)(395.0k)(738.0k)(930.0k)16.0k158.0k193.0k(61.0k)

Cash From Operating Activities

(79.6k)(224.0k)(527.9k)(252.8k)(478.7k)(1.0m)(2.2m)(4.2m)(4.1m)(6.7m)(10.4m)(2.1m)(4.6m)(7.7m)(2.6m)(5.2m)(7.9m)(3.7m)(7.2m)(10.4m)(2.1m)(4.0m)(5.0m)(620.0k)(1.4m)(2.3m)(4.7m)

Cash From Investing Activities

(3.3k)(4.2k)(2.1m)(2.2m)(213.0k)(395.0k)(450.0k)(39.0k)(217.0k)(348.0k)(29.0k)(117.0k)(319.0k)(22.0k)(80.0k)(108.0k)(19.0k)4.0k(18.0k)(21.0k)(45.0k)(57.0k)(43.0k)

Cash From Financing Activities

20.0k1.0m552.9k350.0k677.2k2.1m6.4m8.6m6.5m11.6m16.7m1.5m2.6m5.0m1.9m2.9m7.6m2.5m6.3m7.7m2.3m3.1m972.0k1.1m2.6m6.9m

Net Change in Cash

(59.6k)796.0k25.0k97.2k195.2k1.1m2.0m2.2m2.1m4.5m5.8m(636.0k)(2.2m)(3.1m)(754.0k)(2.5m)(697.0k)(1.2m)(960.0k)(2.8m)(2.1m)(1.7m)(2.0m)331.0k(392.0k)196.0k2.2m

Interest Paid

25.9k25.9k37.4k252.2k259.0k336.0k352.0k15.0k29.0k74.0k15.0k29.0k44.0k32.0k96.0k156.0k63.0k111.0k128.0k51.0k66.0k111.0k29.0k

Income Taxes Paid

Innovation Pharmaceuticals Ratios

USDQ1, 2012